Evidence map›Paper›PMID 37011054›Full record

ArticlePloS one2023

InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma.

Irene Orlow, Keimya D Sadeghi, Sharon N Edmiston, Jessica M Kenney, Cecilia Lezcano, James S Wilmott, Anne E Cust, Richard A Scolyer, Graham J Mann, Tim K Lee and 43 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors at 20 institutions in 4 countries.

Irene OrlowDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.ORCID 0000-0001-6234-6961
Keimya D SadeghiDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Sharon N EdmistonDepartment of Dermatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Jessica M KenneyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Cecilia LezcanoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
James S WilmottMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Anne E CustMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-8991-0013
Graham J MannMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Tim K LeeBritish Columbia Cancer Research Center, Vancouver, British Columbia, Canada.
Hazel BurkeMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Valerie JakrotMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Ping ShangMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Peter M FergusonMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-8335-0406
Tawny W BoyceDepartment of Internal Medicine, University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States of America.
Jennifer S KoDepartment of Pathology, Cleveland Clinic, Cleveland, Ohio, United States of America.
Peter NgoDepartment of Hospital Medicine, Cleveland Clinic, Cleveland, Ohio, United States of America.
Pauline FunchainTaussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Judy R ReesDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
Kelli O'ConnellDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Honglin HaoDepartment of Dermatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Eloise ParrishDepartment of Dermatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Kathleen ConwayDepartment of Dermatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Paul B GoogeDepartment of Dermatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
David W OllilaDepartment of Surgery, Division of Surgical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Stergios J MoschosDepartment of Medicine, Division of Medical Oncology, The University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States of America.
Eva HernandoDepartment of Pathology, New York University Grossman School of Medicine, New York, New York, United States of America.
Douglas HannifordDepartment of Pathology, New York University Grossman School of Medicine, New York, New York, United States of America.
Diana ArgibayDepartment of Pathology, New York University Grossman School of Medicine, New York, New York, United States of America.
Christopher I AmosDepartment of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
Jeffrey E LeeDepartment of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, United States of America.
Iman OsmanDepartment of Urology, New York University Grossman School of Medicine, New York, NY, United States of America.
Li LuoDepartment of Internal Medicine, University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States of America.
Pei-Fen KuanDepartment of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New York, United States of America.ORCID 0000-0001-7861-916X
Arshi AuroraDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Bonnie E Gould RothbergSmilow Cancer Hospital, Yale-New Haven Health System, New Haven, Connecticut, United States of America.
Marcus W BosenbergDepartment of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, United States of America.
Meg R GerstenblithDepartment of Dermatology, University Hospitals Cleveland Medical Center/Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Cheryl ThompsonDepartment of Nutrition, Case Western Reserve University, Cleveland, Ohio, United States of America.
Paul N BognerDepartment of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America.
Ivan P GorlovDepartment of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
Sheri L HolmenDepartment of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, Utah, United States of America.
Elise K BrunsgaardHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah, United States of America.
Yvonne M SaengerDepartment of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York, United States of America.
Ronglai ShenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Venkatraman SeshanDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Eduardo NagoreDepartment of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain.
Marc S ErnstoffDivision of Cancer Treatment and Diagnosis, National Cancer Institute, ImmunoOncology Branch, Developmental Therapeutics Program, Rockville, Maryland, United States of America.
Klaus J BusamDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Colin B BeggDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Nancy E ThomasDepartment of Dermatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Marianne BerwickDepartment of Internal Medicine, University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States of America.
InterMEL Consortium
Memorial Sloan Kettering Cancer Center · USUniversity of North Carolina at Chapel Hill · USThe University of Sydney · AUNew York University · USCleveland Clinic · USUniversity of New Mexico · USBaylor College of Medicine · USUniversity of Utah · USAlbert Einstein College of Medicine · USAustralian National University · AUBC Cancer Agency · CADartmouth College · USFundación Instituto Valenciano de Oncología · ESJohns Hopkins University · USNational Cancer Institute · USPennsylvania State University · USRoswell Park Comprehensive Cancer Center · USStony Brook University · USThe University of Texas MD Anderson Cancer Center · USYale New Haven Health System · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Project 4P50CA225450 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIRCHHOFF, TOMAS · 2019 to 2025
$12.5M
Sex Differences in Methylome Alterations and Mutational Burden in Early Stage MelanomaP01CA206980 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BERWICK, MARIANNE, THOMAS, NANCY E. · 2017 to 2022
$10.1M
NRSA in GeneticsT32GM135128 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Daniel J McKay, JEFF J. SEKELSKY · 2020 to 2026
$5.1M
Efficacy of combined inhibition of BRAF, MEK, and FAK in melanoma patient derived xenograftsR01CA121118 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheri L Holmen · 2007 to 2026
$4.7M
Prognostic markers in metastatic melanomaK08CA151645 · NCI · YALE UNIVERSITY · PI GOULD ROTHBERG, BONNIE ELYSSA · 2010 to 2014
$527k
Development of a new molecular predictor for risk of distant metastases in melanomaR21CA245577 · NCI · UNIVERSITY OF UTAH · PI HOLMEN, SHERI L · 2020 to 2021
$392k
NCI NIH HHS K08 CA151645NCI NIH HHS P01 CA206980NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS P30 CA042014NCI NIH HHS P30 CA118100NCI NIH HHS P50 CA225450NCI NIH HHS R01 CA121118NCI NIH HHS R21 CA245577NIGMS NIH HHS T32 GM135128
6 · The paper itself

Abstract

introductionWe are conducting a multicenter study to identify classifiers predictive of disease-specific survival in patients with primary melanomas. Here we delineate the unique aspects, challenges, and best practices for optimizing a study of generally small-sized pigmented tumor samples including primary melanomas of at least 1.05mm from AJTCC TNM stage IIA-IIID patients. We also evaluated tissue-derived predictors of extracted nucleic acids' quality and success in downstream testing. This ongoing study will target 1,000 melanomas within the international InterMEL consortium.

methodsFollowing a pre-established protocol, participating centers ship formalin-fixed paraffin embedded (FFPE) tissue sections to Memorial Sloan Kettering Cancer Center for the centralized handling, dermatopathology review and histology-guided coextraction of RNA and DNA. Samples are distributed for evaluation of somatic mutations using next gen sequencing (NGS) with the MSK-IMPACTTM assay, methylation-profiling (Infinium MethylationEPIC arrays), and miRNA expression (Nanostring nCounter Human v3 miRNA Expression Assay).

resultsSufficient material was obtained for screening of miRNA expression in 683/685 (99%) eligible melanomas, methylation in 467 (68%), and somatic mutations in 560 (82%). In 446/685 (65%) cases, aliquots of RNA/DNA were sufficient for testing with all three platforms. Among samples evaluated by the time of this analysis, the mean NGS coverage was 249x, 59 (18.6%) samples had coverage below 100x, and 41/414 (10%) failed methylation QC due to low intensity probes or insufficient Meta-Mixed Interquartile (BMIQ)- and single sample (ss)- Noob normalizations. Six of 683 RNAs (1%) failed Nanostring QC due to the low proportion of probes above the minimum threshold. Age of the FFPE tissue blocks (p<0.001) and time elapsed from sectioning to co-extraction (p = 0.002) were associated with methylation screening failures. Melanin reduced the ability to amplify fragments of 200bp or greater (absent/lightly pigmented vs heavily pigmented, p<0.003). Conversely, heavily pigmented tumors rendered greater amounts of RNA (p<0.001), and of RNA above 200 nucleotides (p<0.001).

conclusionOur experience with many archival tissues demonstrates that with careful management of tissue processing and quality control it is possible to conduct multi-omic studies in a complex multi-institutional setting for investigations involving minute quantities of FFPE tumors, as in studies of early-stage melanoma. The study describes, for the first time, the optimal strategy for obtaining archival and limited tumor tissue, the characteristics of the nucleic acids co-extracted from a unique cell lysate, and success rate in downstream applications. In addition, our findings provide an estimate of the anticipated attrition that will guide other large multicenter research and consortia.

Indexed as

MelanomaMicroRNAsNucleic AcidsDNAFormaldehydeHumansParaffin EmbeddingTissue FixationDNAFormaldehydeMicroRNAsNucleic Acids

Identifiers

PMID37011054
PMCPMC10069769
OpenAlexW4362521465

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.